A novel phosphodiesterase 4 inhibitor, AA6216, reduces macrophage activity and fibrosis in the lung

Idiopathic pulmonary fibrosis (IPF) is an intractable disease with poor prognosis, and therapeutic options are limited. While the pathogenic mechanism is unknown, cytokines, such as transforming growth factor (TGF)-β, and immune cells, such as monocytes and macrophages, that produce them, seem to be...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of pharmacology 2020-10, Vol.885, p.173508-173508, Article 173508
Hauptverfasser:	Matsuhira, Takashi, Nishiyama, Osamu, Tabata, Yuji, Kaji, Chizuko, Kubota-Ishida, Natsuki, Chiba, Yasutaka, Sano, Hiroyuki, Iwanaga, Takashi, Tohda, Yuji
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Bleomycin Bronchoalveolar Lavage Fluid - cytology Cell Line Female Humans Macrophage Macrophages - drug effects Macrophages, Alveolar - drug effects Male Mice Mice, Inbred C57BL Mice, Inbred ICR Monocytes - drug effects Phosphodiesterase 4 inhibitor Phosphodiesterase 4 Inhibitors - pharmacology Phosphodiesterase 4 Inhibitors - therapeutic use Pulmonary fibrosis Pulmonary Fibrosis - chemically induced Pulmonary Fibrosis - drug therapy Pulmonary Fibrosis - pathology Transforming Growth Factor beta - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!